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Background. We investigated the level of soluble adhesion molecules in diabetic patients and the eﬀect of the peroxisome
proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone on plasma levels of adhesion molecules and an inﬂammation
marker in type 2 diabetic patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Methods.
A total of 116 diabetic patients with CAD who had undergone PCI were randomized to receive rosiglitazone (4mg/d) or not for 6
months.Plasmalevelsofsolubleintercellularadhesionmolecules(sICAM-1)andP-selectin(sP-selectin)weremeasuredonELISA.
Results. After 6-month rosiglitazone treatment, plasma levels of sICAM-1 were lower than baseline and control group levels (370.4
(332.4–421.9)pg/mLversus423.5(327.4–500.3)pg/mLand404.6(345.2–483.4)pg/mL,P<. 001).Inaddition,plasmalevelsofC-
reactive protein were signiﬁcantly reduced from baseline levels. However, plasma level of sP-selectin was not signiﬁcantly lowered
with rosiglitazone treatment than with control treatment after 6-month follow-up. Conclusions. Rosiglitazone reduces chronic
inﬂammatory responses and improves levels of markers of endothelial dysfunction in patients with diabetes and CAD. PPAR-γ
agonist may have a beneﬁcial eﬀect on the vascular endothelium through its anti-inﬂammatory mechanism and may be useful as
therapy in patients undergoing PCI.
Copyright © 2008 Guang Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Chronic subclinical inﬂammation is increasingly recognized
as possibly contributing to the progression of atherosclerosis
and acute coronary syndromes. The formation and devel-
opment of atherosclerotic lesions involve accumulation of
monocytes and T lymphocytes [1]. The process of leukocyte
adhesion and transendothelial migration is mediated by
cellular adhesion molecules, which are expressed on the
endothelial surface in response to many atherogenic stimuli
[2]. Elevated plasma levels of soluble adhesion molecules
suggest a role in plaque instability and predict the develop-
ment of atherosclerosis and cardiovascular events in patients
with coronary artery disease (CAD) [3, 4]. In addition,
several prospective studies have demonstrated that plasma
level of C-reactive protein (CRP) is an inﬂammatory marker
of cardiovascular disease. Chronic subclinical inﬂammation
is part of the insulin resistance syndrome [5]. Although the
exactcauseofatherosclerosisisnotclear,theimprovementof
metabolic disorders and chronic inﬂammation characterized
by insulin resistance may signiﬁcantly decrease the risk of the
disease.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors that are a subfamily
of the nuclear receptor gene family. PPAR-γ plays a central
role in metabolism and is highly expressed in endothelial
cells, vascular smooth muscle cells, and macrophages [6].
The rosiglitazones are a class of pharmacological com-
pounds with high aﬃnity to PPAR-γ.H o w e v e r ,P P A R -
γ agonists reduce plaque inﬂammation by inhibiting the
activation of several proinﬂammatory genes responsible
for plaque stability through decreasing the expression of2 PPAR Research
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Figure 1: (a) Changes in levels of hemoglobin A1c, (b) fasting plasma insulin, and (c) glucose, as well as (d) HOMA-IR, with 6-month
rosiglitazone treatment. Data are means ± SD. Control group, n = 56; rosiglitazone (RSG) group, n = 60. HbA1c: hemoglobin A1c; HOMA-
IR: homeostasis model assessment-insulin resistance.
adhesion molecules [7, 8]. Troglitazone inhibits the inter-
action between leukocytes and endothelial cells, decreases
the expression of intercellular adhesion molecule-1 (ICAM-
1) in activated endothelial cells, and reduces monocytes
homing to atherosclerotic plaque [9, 10]. Furthermore,
our previous study demonstrated that PPAR-γ agonists
signiﬁcantly reduce homocysteine-induced reactive oxygen
species and secretion of monocyte chemoattractant protein-
1 (MCP-1) in monocytes [11]. Recently, we showed plasma
levels of MCP-1 signiﬁcantly decreased with rosiglitazone
treatment [12, 13]. However, whether PPAR-γ agonists can
exert a beneﬁcial eﬀect on soluble adhesion molecule levels
to promote adhesion and transendothelial migration of
monocytes to endothelium in patients with diabetes and
CAD after percutaneous coronary intervention (PCI) is
unknown.
We aimed to investigate the level of soluble adhesion
molecules in diabetic patients and the eﬀect of rosiglitazone
on plasma levels of adhesion molecules and an inﬂammation
marker in type 2 diabetic patients with CAD after PCI.
2. METHODS
2.1. Subjects
Patients were selected from the cardiovascular internal
medicine practice at Peking University Third Hospital
between October 2002 and September 2005. We included
116 patients, aged 45 to 79 years old, with a diagnosis
of CAD (>50% stenosis seen on angiography) and type 2
diabetes mellitus. Patients with acute myocardial infarction
during the preceding 12 weeks, cardiac insuﬃciency, renal
function impairment, liver function impairment, systemic
inﬂammatory disease, infectious disease, cancer, or a serious
illness that would aﬀect their participation or patients under
insulin treatment were excluded.Guang Wang et al. 3
2.2. Studydesign
All 116 patients had undergone angiography and percu-
taneous coronary intervention. The patients were divided
into two groups for treatment depending on sequence
of patients recruited into the study: control group (56
patients) and rosiglitazone group (60 patients), who received
4mg rosiglitazone daily for 6 months. One patient in the
treatment group withdrew during follow-up because of
recruitment into another clinical trial. Blood was sampled
before and after angiography for 6 months for analysis of
clinical chemistry and inﬂammatory factors. Plasma was
separated and stored at −70
◦C for further analysis.
All subjects gave their written, informed consent. This
study was approved by the Ethics Committee of the Health
Science Center, Peking University.
2.3. Laboratorymeasurements
Blood samples were drawn from an antecubital vein in the
morning after overnight fasting and collected into vacuum
tubes containing EDTA to measure plasma lipid levels. Total
cholesterol(TC),high-densitylipoproteincholesterol(HDL-
C),low-densitylipoproteincholesterol(LDL-C),andtriglyc-
eride (TG) levels were analyzed by colorimetric enzymatic
assays with use of Auto-Analyzer (HITACHI-7170). The
measurements of fasting plasma glucose, fasting insulin, and
hemoglobin A1c were determined at the Central Chemistry
Laboratory, Peking University Third Hospital.
Levels of CRP were measured by the use of an enzyme-
linked immunosorbent assay (ELISA) kit following the man-
ufacturers’ protocols (R&D systems, Minneapolis, Minn,
USA). Plasma levels of soluble ICAM-1 (sICAM-1) and P-
selectin (sP-selectin) were measured by ELISA (GeneMay,
Inc., San Diego, Calif, USA) according to the manufacturer’s
protocols. The estimate of homeostasis model assessment-
insulin resistance (HOMA-IR) was as follows: IR = (fasting
insulin (μU/mL) × fasting glucose (mmol/L))/22.5.
2.4. Statisticalanalysis
Diﬀerences between groups in levels of glucose, TC, LDL-
C, HDL-C were analyzed by Student’s t test. Values for
continuous variables are expressed as means ± SD. Plasma
levelsofsolubleICAM-1aregivenasmediansandrangesand
were assessed by non-parametric tests (Mann Whitney U-
test). Proportions were analyzed by use of the chisquare test.
Av a l u eo fP<. 05 (two-tailed) was considered statistically
signiﬁcant.
3. RESULTS
3.1. Clinicalcharacteristicsofpatients
The characteristics of patients are summarized in Table 1.
The control and rosiglitazone groups did not diﬀer signiﬁ-
cantly in baseline demographics; risk factors for atheroscle-
rosis; prevalence of smoking, hypertension, hyperlipidemia,
and use of other medications; as well as laboratory values
or plasma levels of inﬂammatory factors. The two groups
did not diﬀer in medical therapy during 6-month follow-
up other than use of rosiglitazone or in diabetic duration or
complications.
3.2. Effectsofrosiglitazonetreatmenton
metabolicparameters
After 6-month rosiglitazone treatment, the level of
hemoglobin A1c was signiﬁcantly decreased in the
rosiglitazone group as compared with baseline and control
levels (Figure 1(a); 6.14 ± 0.68% versus 7.15 ± 0.72%
and 6.67 ± 0.65%, P<. 001). Similarly, rosiglitazone
signiﬁcantly decreased the level of fasting plasma insulin
and glucose as compared with baseline and control levels
(7.60 ± 1.15mmol/L versus 13.10 ± 1.84mmol/L and
11.10 ± 1.60mmol/L, P<. 001; 6.04 ± 1.15mmol/L versus
7.10 ± 1.42mmol/L and 7.08 ± 1.23mmol/L, P<. 001;
Figures 1(b)-1(c)). HOMA-IR levels were signiﬁcantly
decreased after 6-month treatment (2.9 ± 0.32 versus
4.12 ± 0.38 and 3.92 ± 0.36, P<. 001, Figure 1(d)), as
expected. However, hemoglobin A1c and fasting plasma
glucose levels were not signiﬁcantly diﬀerent from the
control group at 6-month follow-up (Table 1). In addition,
plasma levels of TC, HDL-C, LDL-C were signiﬁcantly
decreased with rosiglitazone treatment as compared with
baseline levels, with no signiﬁcant diﬀerence between the
rosiglitazone and control group at 6-month follow-up
(Table 2).
Weight gain can be a major drawback in treatment
with a PPAR-γ agonist. Body weight was increased but not
signiﬁcantly from the baseline and control levels after 6-
month rosiglitazone treatment (Table 2).
3.3. Rosiglitazoneeffectonplasmalevelsof
inﬂammatorymarkerssICAM-1,sP-selectin,
andCRP
Plasma sICAM-1 levels were signiﬁcantly decreased in the
rosiglitazone group compared with baseline and control
levelsafter6-monthtreatment(370.4(332.4to421.9)pg/mL
versus 423.5 (327.4 to 500.3) pg/mL and 404.6 (345.2 to
483.4) pg/mL, P<. 001) (Figure 2(a)). Plasma sP-selectin
levels were not signiﬁcantly lower in the rosiglitazone group
than at baseline or in the control group after 6-month
treatment (170.2 (119.2 to 251.9) pg/mL versus 182.5 (127.2
to 212.9) pg/mL and 175.2 (119.2 to 251.8) pg/mL, P>. 05).
Inaddition,plasmalevelsofsICAM-1andsP-selectindidnot
diﬀerfromcontrollevelsbeforeandafter6-monthtreatment
(Figures 2(a)-2(b)).
Plasma CRP levels in the rosiglitazone group were
signiﬁcantly reduced from 1.66 ± 0.23 to 0.88 ± 0.21mg/L
after 6-month treatment (Figure 3) and were signiﬁcantly
lower than in controls after6-month treatment (mean0.88±
0.21 versus 1.69 ± 0.25mg/L, P<. 0001). CRP levels in the
control group did not diﬀer from baseline levels after 6-
month follow-up.4 PPAR Research
Table 1: Baseline clinical characteristics of patients with diabetes and coronary artery disease after percutaneous coronary intervention.
Control n = 56 Rosiglitazone n = 60
Character
Age, years 63.20 ±7.50 61.60 ±7.60
Body mass index 25.50 ±2.70 26.10 ±2.60
Sex (M/F) 45/10 49/11
Risk factors, no.
Hyperlipidemia 24 26
Hypertension 41 42
Smoking 23 28
Parameters (levels)
Cholesterol, mmol/L 4.80 ±0.57 4.85 ±0.48
High-density lipoprotein, mmol/L 1.02 ±0.15 1.04 ±0.12
Low-density lipoprotein, mmol/L 2.87 ±0.63 2.93 ±0.78
Triglycerides, mmol/L 2.01 ±0.70 1.99 ±0.63
Fasting insulin, mμ/L 11.40 ±1.72 13.10 ±1.84
Fasting plasma glucose, (mmol/L) 7.20 ±1.35 7.10 ±1.42
HbA1c, % 7.23 ±0.68 7.15 ±0.72
HOMA-IR 3.85 ±0.38 4.12 ±0.38
CRP, mg/dL 1.84 ±0.21 1.66 ±0.23
sICAM-1, ng/mL 407.1 (344.3–476.1) 423.5 (327.4–421.9)
sP-selectin, ng/mL 172.6 (123.3–223.3) 182.5 (127.2–212.9)
Medication
Aspirin 55 60
B-blocker 51 53
Lipid-lowering drugs 51 58
Nitrates 24 23
Ca-Antagonists 7 7
ACE inhibitors 43 43
Other antidiabetic drugs 34 35
Biguanides 22 24
Acarbose 8 8
Sulfonylureas 4 5
HOMA-IR: homeostasis-model-assessment insulin resistance; CRP: C-reactive protein; sICAM-1: soluble intercellular adhesion molecule-1; HbA1c:
hemoglobin A1c; sP-selectin: soluble P selectin. Data are means ± SD or medians and ranges.
Table 2: Metabolic features of patients before and 6 months after rosiglitazone treatment. Values are mean ± SD.
Metabolic parameters Control group (n = 56) Rosiglitazone group (n = 60)
Baseline after 6 months Baseline after 6 months
Total cholesterol, mmol/L 4.80 ±0.57 4.33 ±0.51
∗ 4.85 ±0.48 4.27 ±0.42#
High-density lipoprotein, mmol/L 1.02 ±0.15 1.26 ±0.11# 1.04 ±0.12 1.35 ±0.15#
Low-density lipoprotein, mmol/L 2.87 ±0.63 2.67 ±0.55 2.93 ±0.78 2.53 ±0.73
∗
Triglycerides, mmol/L 2.01 ±0.70 1.75 ±0.61 1.99 ±0.63 1.62 ±0.62
Body mass index 25.50 ± 2.72 5 .37 ±2.34 26.17 ±2.60 26.49 ±2.11
∗P<. 05 compared to baseline;
#P<. 01 compared to baseline.
3.4. Rosiglitazoneeffectoncoronaryeventsduring
6-monthfollow-up
Eleven patients in the rosiglitazone group had coronary
events (recurrent unstable angina in 8, percutaneous trans-
lational coronary angioplasty in 2, and coronary artery
bypass grafting in 1) versus 14 patients in the control group
(recurrent unstable angina in 7, percutaneous translational
coronary angioplasty in 2, sudden death in 1, and coronary
artery bypass grafting in 4) at 6-month follow-up, with no
signiﬁcant diﬀerence between the two groups.Guang Wang et al. 5
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Figure 2: Eﬀect of rosiglitazone treatment on plasma levels
of soluble ICAM-1 (sICAM-1) (a) and P-selectin (sP-selectin)
(b) in patients with diabetes and coronary artery disease after
percutaneous coronary intervention. Data are medians and ranges.
Control group, n = 56; rosiglitazone (RSG) group, n = 60.
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Figure 3: Eﬀect of rosiglitazone treatment on plasma levels of C-
reactiveprotein(CRP)inpatientswithdiabetesandcoronaryartery
diseaseafterpercutaneouscoronaryintervention.Dataaremeans ±
SD. Control group, n = 56; rosiglitazone (RSG) group, n = 60.
4. DISCUSSION
Chronic low-grade inﬂammation is associated with cardio-
vasculareventsinpatientswithCADordiabetes.Endothelial
cell expression of adhesion molecules and the adhesion
of leukocytes to the endothelium play a key role in the
development ofatheroscleroticplaqueandplaqueinstability.
Endothelial function may be assessed by measuring plasma
levels of endothelial products such as soluble adhesion
molecules. Our study demonstrates that 6-month treat-
ment with the PPAR-γ rosiglitazone treatment signiﬁcantly
improved metabolic parameters, including insulin resistance
in patients with diabetes and CAD. In addition, rosiglita-
zone treatment signiﬁcantly decreased the plasma levels of
sICAM-1 and inﬂammatory marker CRP as compared with
baseline and control levels.
Atherosclerosis is characterized by the recruitment of
monocytes and lymphocytes to the artery wall. A number
of studies have determined the important role of adhesion
molecules in atherosclerotic plaque formation [2, 3]. P-
selectin is responsible in part for the adhesion of certain
leukocytes and platelets to the endothelium. Animal models
have also shown the important role of P-selectin in the
process of atherogenesis. For example, increased P-selectin
expression has been demonstrated in active atherosclerotic
plaques. Increased levels of soluble P-selectin in plasma
have also been demonstrated in CAD [14]. Several stud-
ies have demonstrated plasma levels of CRP positively
associated with risk of cardiovascular disease and clinical
events. CRP may exert a direct eﬀect in promoting the
progression of atherosclerosis and plaque instability [15].
Rosiglitazone signiﬁcantly reduces levels of markers of
endothelial cell activation and CRP in CAD patients without
diabetes; potential mechanisms include insulin sensitization
and modiﬁcation of inﬂammation within the vessel wall
[16].
PPAR-γ is expressed in most cells of the vascular
wall and atherosclerotic lesions [17, 18]. The binding of
monocytes to adhesion molecules expressed on the surface
of endothelial cells and their inﬁltration into the suben-
dothelial space may be reduced by PPARγ agonists. The
PPAR-γ agonist troglitazone inhibits the interaction between
leukocyte endothelial cells and decreases the expression of
vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1
in activated endothelial cells and reduces monocyte homing
to atherosclerotic plaque [9, 10]. In recent years, PPAR-
γ agonists have been increasingly used to treat patients
with type 2 diabetes mellitus. Such treatment is aimed at
reducing the incidence of vascular complications, including
myocardial infarction and restenosis after PCI. Animal
studies have shown that troglitazone prevents neointimal
formation after endothelial balloon injury in rats [18].
A recent study showed that pioglitazone suppresses in-
stent restenosis by limiting local inﬂammatory pathways in
atherosclerotic rabbits [19]. Clinical studies have shown that
pioglitazone reduces neointimal volume after coronary stent
implantation in nondiabetic patients [20]. As well, rosiglita-
zone improves diabetes compensation, signiﬁcantly reducing
VCAM-1 level, and E-selectin concentrations in patients6 PPAR Research
with diabetes [21]. Plasma concentrations of CRP and E-
selectin were shown to decrease signiﬁcantly after rosiglita-
zone treatment for 3 months in diabetic patients, although
concentrations of ICAM-1 and VCAM-1 did not decrease
[22]. Recently, we showed that plasma levels of MCP-1
and hyperresponsiveness of low-dose lipopolysaccharide-
induced MCP-1 secretion from monocytes were signiﬁcantly
reduced by rosiglitazone treatment in patients with type
2 diabetes and serious vascular disease [15]. Therapy with
rosiglitazone decreased the serum levels of MCP-1 in obese
type-2 diabetic patients [23]. As well, pioglitazone reduces
the levels of ICAM-1 and VCAM-1 in obese patients without
diabetes, without aﬀecting soluble E-selectin levels [24].
In the present study, we demonstrated further that
rosiglitazonesigniﬁcantlydecreasedplasmasICAM-1levelin
diabeticpatientswithCADafterPCI.However,plasmalevels
of sP-selectin were not changed signiﬁcantly by rosiglitazone
treatment. Given that chronic subclinical inﬂammation
is important in atherosclerosis and restenosis after PCI,
inhibiting the proinﬂammatory adhesion molecule sICAM-
1 and CRP levels by rosiglitazone, might have potentially
beneﬁcial eﬀects in type 2 diabetic patients with CAD.
Patients with insulin resistance also have enhanced
risk of atherosclerosis. Chronic inﬂammation may play an
important role in the development of insulin resistance
and endothelial dysfunction. PPAR-γ agonists may modulate
insulin action, which results in change in expression of a
number of genes involved in glucose level, lipid metabolism,
and inﬂammation. These changes are associated with the
reversal of many components of the insulin resistance
syndrome. Hence, in our study, the reduction in inﬂam-
matory marker levels may be due to a collective eﬀect of
rosiglitazone and better metabolic control. Recently, Ryan
et al. [24] reported that pioglitazone treatment improved
insulin resistance and endothelial function and reduced
arterial stiﬀness in obese men. Our results, together with
previous ones, show that fasting plasma glucose, insulin,
and hemoglobin A1c levels, as well as HOMA-IR, are all
decreased signiﬁcantly by 6-month rosiglitazone treatment.
Thus, the reversal of the insulin resistance syndrome with
rosiglitazone is associated with improved cardiovascular risk
factors in patients with diabetes and CAD after PCI.
In conclusion, antidiabetic rosiglitazone therapy may
play an important role in protecting endothelial function
by normalizing the metabolic disorders of diabetes mellitus
and depressing the chronic inﬂammatory response of the
vascularwall,eventuallyreducingtheoccurrenceofcoronary
events and restenosis after PCI in type 2 diabetic patients
with CAD.
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